AbCellera Biologics (ABCL) Deferred Taxes (2021)

AbCellera Biologics (ABCL) reported Deferred Taxes of $1.2 million for Q4 2021, up 131.05% quarter-over-quarter from -$4.0 million in Q3 2021.

AbCellera Biologics (ABCL) Deferred Taxes (2021) Analysis & Trends

AbCellera Biologics has reported Deferred Taxes for 1 years, with the latest figure at $1.2 million in Q4 2021.

For the quarter ending Q4 2021, Deferred Taxes changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2021 stood at -$2.0 million (changed N/A YoY), and the FY2023 full-year result was $2.0 million, up 192.72% from the prior year.
Deferred Taxes for Q4 2021 stood at $1.2 million, up from -$4.0 million in the prior quarter.
The five-year high for Deferred Taxes was $1.2 million in Q4 2021, with the low at -$4.0 million in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-859,000.00
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-65.30 Mn
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	AbCellera Biologics	1.55 Bn	1.44 Bn	-	-

Download Data